Epigenetics in cancer: implications for early detection and prevention.

[1]  Hui-li Chen,et al.  Alteration of N-acetylglucosaminyltransferases in pancreatic carcinoma , 1998, Glycoconjugate Journal.

[2]  P. Guldberg,et al.  DNA methylation: an epigenetic pathway to cancer and a promising target for anticancer therapy. , 2002, Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology.

[3]  J. Christman,et al.  5-Azacytidine and 5-aza-2′-deoxycytidine as inhibitors of DNA methylation: mechanistic studies and their implications for cancer therapy , 2002, Oncogene.

[4]  Peter A. Jones,et al.  The fundamental role of epigenetic events in cancer , 2002, Nature Reviews Genetics.

[5]  R. Pili,et al.  Endogenous reactivation of the RARbeta2 tumor suppressor gene epigenetically silenced in breast cancer. , 2002, Cancer research.

[6]  D. Sidransky,et al.  I105V polymorphism and promoter methylation of the GSTP1 gene in prostate adenocarcinoma. , 2002, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[7]  M. Toyota,et al.  Inactivation of p57KIP2 by regional promoter hypermethylation and histone deacetylation in human tumors , 2002, Oncogene.

[8]  M. Surani,et al.  Genetics: Immaculate misconception , 2002, Nature.

[9]  Robert Brown,et al.  Epigenomics and epigenetic therapy of cancer. , 2002, Trends in molecular medicine.

[10]  P. Laird,et al.  Hierarchical clustering of lung cancer cell lines using DNA methylation markers. , 2002, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[11]  Suna Wang,et al.  Hypermethylation of the p14(ARF) gene in ulcerative colitis-associated colorectal carcinogenesis. , 2002, Cancer research.

[12]  M. Toyota,et al.  Aberrant methylation and histone deacetylation of cyclooxygenase 2 in gastric cancer , 2002, International journal of cancer.

[13]  J. Issa.  The Epigenetics of Colorectal Cancer , 2000, Current opinion in gastroenterology.

[14]  C. Rudin,et al.  Mobile Genetic Element Activation and Genotoxic Cancer Therapy , 2002, American journal of pharmacogenomics : genomics-related research in drug development and clinical practice.

[15]  S. K. Srivastava,et al.  Meeting Highlights: National Cancer Institute Workshop on Molecular Signatures of Infectious Agents , 2002, Disease markers.

[16]  S. Piantadosi,et al.  Reversal of GSTP1 CpG island hypermethylation and reactivation of pi-class glutathione S-transferase (GSTP1) expression in human prostate cancer cells by treatment with procainamide. , 2001, Cancer research.

[17]  J. Brooks,et al.  Preneoplastic Prostate Lesions , 2001, Annals of the New York Academy of Sciences.

[18]  D. Sidransky,et al.  Quantitation of GSTP1 methylation in non-neoplastic prostatic tissue and organ-confined prostate adenocarcinoma. , 2001, Journal of the National Cancer Institute.

[19]  W. Wilson,et al.  Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report. , 2001, Blood.

[20]  E. Verdin,et al.  Regulation of global acetylation in mitosis through loss of histone acetyltransferases and deacetylases from chromatin. , 2001, The Journal of biological chemistry.

[21]  C. Boshoff,et al.  Is KSHV lytic growth induced by a methylation-sensitive switch? , 2001, Trends in microbiology.

[22]  R. Jaenisch,et al.  Nuclear Cloning and Epigenetic Reprogramming of the Genome , 2001, Science.

[23]  C. Allis,et al.  Translating the Histone Code , 2001, Science.

[24]  K. Nephew,et al.  DNA methylation in ovarian cancer. II. Expression of DNA methyltransferases in ovarian cancer cell lines and normal ovarian epithelial cells. , 2001, Gynecologic oncology.

[25]  K. Nephew,et al.  DNA methylation and ovarian cancer. I. Analysis of CpG island hypermethylation in human ovarian cancer using differential methylation hybridization. , 2001, Gynecologic oncology.

[26]  R. Momparler,et al.  Antineoplastic action of 5-aza-2′-deoxycytidine and histone deacetylase inhibitor and their effect on the expression of retinoic acid receptor β and estrogen receptor α genes in breast carcinoma cells , 2001, Cancer Chemotherapy and Pharmacology.

[27]  C. Allis,et al.  Histone methylation versus histone acetylation: new insights into epigenetic regulation. , 2001, Current opinion in cell biology.

[28]  P. Laird,et al.  Adenocarcinoma Epigenetic Patterns in the Progression of Esophageal Updated Version , 2001 .

[29]  T. DeWeese,et al.  The molecular pathogenesis of prostate cancer: Implications for prostate cancer prevention. , 2001, Urology.

[30]  M. Corbellino,et al.  Activation of latent Kaposi's sarcoma-associated herpesvirus by demethylation of the promoter of the lytic transactivator , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[31]  F. Ding,et al.  Genomic Imprinting Disrupted by a Maternal Effect Mutation in the Dnmt1 Gene , 2001, Cell.

[32]  J. Minárovits,et al.  Protein-DNA Binding and CpG Methylation at Nucleotide Resolution of Latency-Associated Promoters Qp, Cp, and LMP1p of Epstein-Barr Virus , 2001, Journal of Virology.

[33]  S. Meltzer,et al.  Promoter methylation regulates Helicobacter pylori-stimulated cyclooxygenase-2 expression in gastric epithelial cells. , 2001, Cancer research.

[34]  J. Minárovits,et al.  Epigenetics of Latent Epstein-Barr Virus Genomes: High Resolution Methylation Analysis of the Bidirectional Promoter Region of Latent Membrane Protein 1 and 2B Genes , 2001, Biological chemistry.

[35]  A. Feinberg.  Cancer epigenetics takes center stage. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[36]  A. Rickinson,et al.  Methylation of Transcription Factor Binding Sites in the Epstein-Barr Virus Latent Cycle Promoter Wp Coincides with Promoter Down-Regulation during Virus-Induced B-Cell Transformation , 2000, Journal of Virology.

[37]  W. Baek,et al.  5-Aza-2'-deoxycytidine leads to down-regulation of aberrant p16INK4A RNA transcripts and restores the functional retinoblastoma protein pathway in hepatocellular carcinoma cell lines. , 2000, Cancer letters.

[38]  C. Redi,et al.  Nuclear transfer, genome reprogramming and novel opportunities in cell therapy , 2000, Journal of endocrinological investigation.

[39]  I. Ernberg,et al.  Differences in the immunogenicity of latent membrane protein 1 (LMP1) encoded by Epstein-Barr virus genomes derived from LMP1-positive and -negative nasopharyngeal carcinoma. , 2000, Cancer research.

[40]  J. Herman,et al.  DNA hypermethylation in tumorigenesis: epigenetics joins genetics. , 2000, Trends in genetics : TIG.

[41]  B. Tycko,et al.  Epigenetic gene silencing in cancer. , 2000, The Journal of clinical investigation.

[42]  K. Robertson.  The role of DNA methylation in modulating Epstein-Barr virus gene expression. , 2000, Current topics in microbiology and immunology.

[43]  A. Wolffe,et al.  DNA methylation and histone deacetylation in the control of gene expression: basic biochemistry to human development and disease. , 2000, Gene expression.

[44]  A. Mintz,et al.  Cancer genetics/epigenetics and the X chromosome: possible new links for malignant glioma pathogenesis and immune-based therapies. , 2000, Critical reviews in oncogenesis.

[45]  A. Feinberg.  DNA methylation, genomic imprinting and cancer. , 2000, Current topics in microbiology and immunology.

[46]  J. Herman,et al.  hMLH1 promoter hypermethylation is an early event in human endometrial tumorigenesis. , 1999, The American journal of pathology.

[47]  C. Klein,et al.  Nickel carcinogenesis, mutation, epigenetics, or selection. , 1999, Environmental health perspectives.

[48]  E. Ballestar,et al.  Mi-2 complex couples DNA methylation to chromatin remodelling and histone deacetylation , 1999, Nature Genetics.

[49]  Paul Tempst,et al.  MBD2 is a transcriptional repressor belonging to the MeCP1 histone deacetylase complex , 1999, Nature Genetics.

[50]  Q. Tao,et al.  Methylation status of the Epstein-Barr virus major latent promoter C in iatrogenic B cell lymphoproliferative disease. Application of PCR-based analysis. , 1999, The American journal of pathology.

[51]  G. Gaudernack,et al.  Genomic instability, DNA methylation, and natural selection in colorectal carcinogenesis. , 1999, Seminars in cancer biology.

[52]  J. Herman,et al.  Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia. , 1999, Cancer research.

[53]  Peter A. Jones,et al.  Cancer-epigenetics comes of age , 1999, Nature Genetics.

[54]  G. Gaudernack,et al.  Carcinogenesis and natural selection: a new perspective to the genetics and epigenetics of colorectal cancer. , 1999, Advances in cancer research.

[55]  Hao Wang,et al.  The influence of the p53 gene on the in vitro chemosensitivity of colorectal cancer cells , 1999, Journal of Cancer Research and Clinical Oncology.

[56]  J. Herman,et al.  Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA from non-small cell lung cancer patients. , 1999, Cancer research.

[57]  S Srivastava,et al.  A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. , 1998, Cancer research.

[58]  K. Kinzler,et al.  Landscaping the Cancer Terrain , 1998, Science.

[59]  M. Surani.  Imprinting and the Initiation of Gene Silencing in the Germ Line , 1998, Cell.

[60]  J. Issa,et al.  The role of epigenetics in cancer , 1998 .

[61]  M. Newton,et al.  Overcoming cellular senescence in human cancer pathogenesis. , 1998, Genes & development.

[62]  S. Baylin.  Tying It All Together: Epigenetics, Genetics, Cell Cycle, and Cancer , 1997, Science.

[63]  S. Côté,et al.  Pharmacological approach for optimization of the dose schedule of 5-Aza-2’-deoxycytidine (Decitabine) for the therapy of leukemia , 1997, Leukemia.

[64]  Peter W. Laird,et al.  THE ROLE OF DNA METHYLATION IN CANCER GENETICS AND EPIGENETICS , 1996 .

[65]  K. Kinzler,et al.  Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability. , 1995, Science.

[66]  J. Goodman,et al.  Alterations in the methylation status and expression of the raf oncogene in phenobarbital‐induced and spontaneous B6C3F1 mouse liver tumors , 1994, Molecular carcinogenesis.

[67]  H. Novotná,et al.  Hypomethylation of CCGG sites in the 3' region of H-ras protooncogene is frequent and is associated with H-ras allele loss in non-small cell lung cancer. , 1994, Cancer research.

[68]  John Calvin Reed,et al.  bcl-2 Gene hypomethylation and high-level expression in B-cell chronic lymphocytic leukemia , 1993 .

[69]  G. Mufti,et al.  Methylation status within exon 3 of the c-myc gene as a prognostic marker in myeloma and leukaemia. , 1993, Leukemia research.

[70]  R. Gambari,et al.  DNA methylation of the Ha-ras-1 oncogene in neoplastic cells. , 1989, Anticancer Research.

[71]  P. M. Rao,et al.  Studies on hypomethylation of liver DNA during early stages of chemical carcinogenesis in rat liver. , 1989, Carcinogenesis.

[72]  P. Jones,et al.  Patterns of DNA methylation and gene expression in human tumor cell lines. , 1986, Cancer research.

[73]  A. Feinberg,et al.  Hypomethylation of ras oncogenes in primary human cancers. , 1983, Biochemical and biophysical research communications.

[74]  A. Feinberg,et al.  Hypomethylation distinguishes genes of some human cancers from their normal counterparts , 1983, Nature.